Why the study?
While M-TEER is established for certain high-risk severe degenerative or secondary MR patients, evidence and considerations for patients excluded from key trials needed comprehensive review.
Does transcatheter edge-to-edge repair of mitral valve (M-TEER) improve outcomes in patients with severe mitral regurgitation excluded from key trials?
Does transcatheter edge-to-edge repair of mitral valve (M-TEER) improve outcomes in patients with severe mitral regurgitation excluded from key trials?
No takes yet. Share an insight, caveat, or question.
M-TEER may be a feasible and beneficial option for patients with severe mitral regurgitation who fall outside the inclusion criteria of major pivotal trials.
Background: Transcatheter edge-to-edge repair of mitral valve (M-TEER) is reasonable consideration in symptomatic patients with severe degenerative mitral regurgitation (MR) who are at high or prohibitive risk of surgical repair or replacement. In symptomatic patients on maximally tolerated medical therapy with severe secondary MR from left ventricular systolic dysfunction, M-TEER is reasonable therapeutic option. Methods: In this review, we present a comprehensive overview of the most recent literature and considerations for M-TEER in patients excluded from key trials. These include patients with cardiogenic shock, acute ischemic MR, atrial functional MR, failed surgical mitral valve prosthesis and pulmonary hypertension. Conclusions: M-TEER is feasible and a reasonable alternative option for these patient populations with a significant clinical benefit. However, randomized clinical trials are needed to ascertain findings from these observational studies.
Imran et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: